ENLV Enlivex Therapeutics Ltd.
Healthcare$0.68+0.00%OpenMarket Cap: $16.4M
As of 2026-05-26
Valuation
P/E (TTM)
0.02
PEG
0.00
P/B
0.02
P/S
0.00
EV/EBITDA
-1.12
DCF Value
$-0.04
FCF Yield
-63.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
248.1%
ROA
53.1%
ROIC
-0.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $0.00 | -Infinity% | $-5.9M | $1.24B | $— | — |
| FY null | $0.00 | -Infinity% | $-15.0M | $1.24B | $— | — |
| Q3 null | $0.00 | -Infinity% | $-2.6M | $-2.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-3.1M | $-1.9M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-3.5M | $-3.5M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-5.6M | $-5.2M | $— | — |
| FY null | $0.00 | -Infinity% | $-15.5M | $-15.0M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-3.1M | $-2.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-3.0M | $-3.1M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-4.0M | $-4.1M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-6.1M | $-9.1M | $-0.49 | — |
| FY null | $0.00 | -Infinity% | $-29.4M | $-29.1M | $— | — |